• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity.融合阴性横纹肌肉瘤伴弥漫性骨转移和显著化疗敏感性。
BMJ Case Rep. 2022 Aug 29;15(8):e250236. doi: 10.1136/bcr-2022-250236.
2
[Paratesticular rhabdomyosarcoma: a case report].[睾丸旁横纹肌肉瘤:一例报告]
Hinyokika Kiyo. 1990 Mar;36(3):363-6.
3
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.儿童肿瘤学组软组织肉瘤委员会的报告:2型低风险横纹肌肉瘤患者减少环磷酰胺剂量与复发风险增加相关。
Cancer. 2017 Jun 15;123(12):2368-2375. doi: 10.1002/cncr.30613. Epub 2017 Feb 17.
4
Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study.儿童和青少年横纹肌肉瘤诊断时的骨髓转移。来自横纹肌肉瘤协作组研究的报告。
Cancer. 1984 Jan 15;53(2):368-73. doi: 10.1002/1097-0142(19840115)53:2<368::aid-cncr2820530233>3.0.co;2-3.
5
[A case of metastatic paratesticular rhabdomyosarcoma in an adult successfully treated with multidrug combination chemotherapy].[一例成人转移性睾丸旁横纹肌肉瘤经多药联合化疗成功治疗的病例]
Hinyokika Kiyo. 2010 Sep;56(9):531-3.
6
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.在中危横纹肌肉瘤患儿、青少年和年轻成人中添加替西罗莫司联合化疗(ARST1431):来自儿童肿瘤学组的一项随机、开放标签、3 期试验。
Lancet Oncol. 2024 Jul;25(7):912-921. doi: 10.1016/S1470-2045(24)00255-9.
7
[A case of paratesticular rhabdomyosarcoma].[一例睾丸旁横纹肌肉瘤]
Hinyokika Kiyo. 1990 Sep;36(9):1089-92.
8
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.长春新碱、伊立替康联合长春新碱、放线菌素 D 和环磷酰胺不能改善中危横纹肌肉瘤的预后:来自儿童肿瘤学组的报告。
J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9.
9
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.异环磷酰胺和依托泊苷与放疗及联合化疗联用时,在小儿转移性横纹肌肉瘤的治疗中优于长春新碱和美法仑:横纹肌肉瘤协作组的报告
J Pediatr Hematol Oncol. 2001 May;23(4):225-33. doi: 10.1097/00043426-200105000-00010.
10
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.长春新碱、放线菌素和环磷酰胺与长春新碱、放线菌素和环磷酰胺交替联合长春新碱、拓扑替康和环磷酰胺治疗中危横纹肌肉瘤的疗效比较:儿童肿瘤学组D9803研究
J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21.

本文引用的文献

1
Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.局部控制和外科淋巴结评估对局限性腹膜后横纹肌肉瘤的影响:来自儿童肿瘤学组软组织肉瘤委员会的报告。
Int J Cancer. 2020 Dec 1;147(11):3168-3176. doi: 10.1002/ijc.33143. Epub 2020 Jul 11.
2
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.长春瑞滨联合持续低剂量环磷酰胺作为高危横纹肌肉瘤(RMS 2005)患者的维持化疗:一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2019 Nov;20(11):1566-1575. doi: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24.
3
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.除了既定的临床预后预测因素外,利用 FOXO1 融合状态对儿童横纹肌肉瘤进行风险分层的精细化:来自儿童肿瘤学组的报告。
Cancer Med. 2019 Oct;8(14):6437-6448. doi: 10.1002/cam4.2504. Epub 2019 Aug 27.
4
Consensus and controversies regarding the treatment of rhabdomyosarcoma.关于横纹肌肉瘤治疗的共识与争议
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26809. Epub 2017 Sep 14.
5
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.多激酶血管内皮生长因子(VEGF)抑制剂帕唑帕尼与丝裂原活化蛋白激酶(MEK)抑制剂曲美替尼联合治疗晚期软组织肉瘤的Ib/II期安全性和疗效研究。
Clin Cancer Res. 2017 Aug 1;23(15):4027-4034. doi: 10.1158/1078-0432.CCR-17-0272. Epub 2017 Apr 4.
6
Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature.骨原发性肺泡横纹肌肉瘤:两例报告并文献复习
Diagn Pathol. 2016 Oct 18;11(1):99. doi: 10.1186/s13000-016-0552-9.
7
Pazopanib in the management of advanced soft tissue sarcomas.帕唑帕尼用于晚期软组织肉瘤的治疗
Ther Clin Risk Manag. 2016 Jun 9;12:941-55. doi: 10.2147/TCRM.S84792. eCollection 2016.
8
Severe Tumor Lysis Syndrome and Acute Pulmonary Edema Requiring Extracorporeal Membrane Oxygenation Following Initiation of Chemotherapy for Metastatic Alveolar Rhabdomyosarcoma.转移性肺泡横纹肌肉瘤化疗后出现严重肿瘤溶解综合征及急性肺水肿并需体外膜肺氧合治疗
Pediatr Blood Cancer. 2016 May;63(5):928-30. doi: 10.1002/pbc.25879. Epub 2015 Dec 29.
9
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.帕唑帕尼治疗晚期软组织肉瘤的长期缓解者和幸存者:欧洲癌症研究与治疗组织(EORTC)两项临床试验62043和62072的亚组分析
Ann Oncol. 2014 Mar;25(3):719-724. doi: 10.1093/annonc/mdt586. Epub 2014 Feb 6.
10
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.帕唑帕尼在软组织肉瘤和其他难治性实体瘤儿童患者中的 I 期药代动力学和药效学研究:儿童肿瘤学组 I 期联盟报告。
J Clin Oncol. 2013 Aug 20;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914. Epub 2013 Jul 15.

融合阴性横纹肌肉瘤伴弥漫性骨转移和显著化疗敏感性。

Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity.

机构信息

Department of Pediatrics, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA.

Department of Hematology/Oncology and Department of Palliative Medicine, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA.

出版信息

BMJ Case Rep. 2022 Aug 29;15(8):e250236. doi: 10.1136/bcr-2022-250236.

DOI:10.1136/bcr-2022-250236
PMID:36038153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9438076/
Abstract

In this report, we describe the case of an adolescent male with an unusual case of fusion-negative, paratesticular alveolar rhabdomyosarcoma who presented with spontaneous tumour lysis syndrome and diffuse bony metastases throughout the axial and appendicular skeleton with additional significant bone marrow involvement. Both spontaneous tumour lysis syndrome and diffuse bony metastases are extremely unusual for rhabdomyosarcoma. On the backbone of standard vincristine, dactinomycin and cyclophosphamide (VAC) chemotherapy, the only local control was orchiectomy at 15 weeks, with no radiation administered due to the initially diffuse nature of the disease and rapid response to chemotherapy. Following 43 weeks of VAC, a year-long maintenance phase with pazopanib was given which was well tolerated. The patient remains in remission now 4 years after completion of therapy.

摘要

在本报告中,我们描述了一例融合阴性、副睾区肺泡横纹肌肉瘤的青少年男性病例,该患者表现为自发性肿瘤溶解综合征和弥漫性骨转移,累及轴骨和附肢骨,骨髓广泛受累。自发性肿瘤溶解综合征和弥漫性骨转移对横纹肌肉瘤来说极其罕见。在标准长春新碱、放线菌素 D 和环磷酰胺(VAC)化疗的基础上,唯一的局部控制手段是 15 周时进行的睾丸切除术,由于疾病最初呈弥漫性且对化疗反应迅速,因此未进行放疗。在接受 VAC 治疗 43 周后,给予帕唑帕尼进行为期一年的维持治疗,患者耐受性良好。在完成治疗后 4 年,患者仍处于缓解期。